Clinical Effect of Osimertinib Combined with Pemetrexed and Cisplatin in the Treatment of EGFR Mutation Positive Advanced Non-small Cell Lung Cancer
Objective To analyze the clinical effect of osimertinib combined with pemetrexed and cisplatin in the treatment of epidermal growth factor receptor(EGFR)mutation positive advanced non-small cell lung cancer(NSCLC).Methods A total of 148 patients with EGFR mutation positive advanced NSCLC in Nanyang Central Hospital from February 2020 to February 2022 were selected and randomly divided into targeted therapy group and chemotherapy group,with 74 cases in each group.The chemotherapy group was treated with pemetrexed and cisplatin,and the targeted therapy group was treated with osimertinib combined with pemetrexed and cisplatin.The disease control rate,T lymphocyte subsets(CD4+,CD8+),angiogenesis indicators(TK1,VEGF),serum tumor markers(CEA,CA50,CA1 25),KPS score,and the incidence of adverse reactions were compared between the two groups.Results The disease control rate of the targeted therapy group was 60.81％(45/74),which was higher than that of the chemotherapy group(44.59％,33/74)(P＜0.05).After treatment,CD4+in the targeted therapy group was higher than that in the chemotherapy group,and CD8+was lower than that in the chemotherapy group(P＜0.05).After treatment,TK1 and VEGF in the targeted therapy group were lower than those in the chemotherapy group(P＜0.05).After treatment,the levels of serum CEA,CA50 and CA125 in the targeted therapy group were lower than those in the chemotherapy group(P＜0.05).After treatment,the KPS score of the targeted therapy group was higher than that of the chemotherapy group(P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Osimertinib combined with pemetrexed and cisplatin in the treatment of EGFR mutation positive advanced NSCLC can improve immune function,inhibit angiogenesis,reduce tumor markers,improve disease control rate,improve body function,and Good security.
万方数据
维普
